Abstract
Transsphenoidal surgery is the treatment of choice for large non-functioning pituitary adenomas (NFPA) and symptomatic patients. The therapeutic strategies for the management of NFPA after surgery, i.e., watchful waiting, irradiation, or medical therapy have not been compared by randomized controlled trials. Slow re-growth is common, but the natural history of untreated tumors is variable. Conservative follow-up is associated with progression rates of over 40 %. Radiation is highly effective in preventing residual tumor growth, but has serious long-term side effects. Finally, no medications are currently approved for the treatment of NFPA. In this review, we present our view of the optimal management of these tumors, which includes risk stratification for the identification of high-risk patients suitable for active intervention, leaving low-risk patients for careful monitoring.
Similar content being viewed by others
References
M. Al-Shraim, S.L. Asa, The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol. 111, 1–7 (2006)
W. Saeger, D.K. Lüdecke, M. Buchfelder, R. Fahlbusch, H.J. Quabbe, S. Petersenn, Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 156, 203–216 (2007)
S.L. Asa, Practical pituitary pathology. What does the pathologist need to know? Arch. Pathol. Lab. Med. 132, 1231–1240 (2008)
H. Nishioka, M. Ozgur, S.L. Asa, N. Inoshita, N. Fukuhara, K. Horiguchi, S. Yamada, The crucial role of pituitary transcription factors in the accurate classification of hormone-negative nonfunctioning pituitary adenomas. Endocrine Society Meeting 2014, OR09-2
Y. Greenman, N. Stern, Non-functioning pituitary adenomas. Best Pract. Res. Clin. Endocrinol. Metab. 23, 625–638 (2009)
M. Losa, P. Mortini, R. Barzaghi, P. Ribotto, M.R. Terreni, S.B. Marzoli, S. Pieralli, M. Giovanelli, Early results of surgery in patients with nonfunctioning pituitary adenomas and analysis of the risk of tumor recurrence. J. Neurosurg. 108, 525–532 (2008)
O.M. Dekkers, A.M. Pereira, J.H.C. Roelfsema, J.H. Voormolen, K.J. Neelis, M.A. Schroijen, J.W. Smit, J.A. Romijn, Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J. Clin. Endocrinol. Metab. 91, 1796–1801 (2006)
P. Nomikos, C. Ladar, R. Fahlbusch, M. Buchfelder, Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas—a study on 721 patients. Acta Neurochir. 146, 27–35 (2004)
Y. Greenman, K. Tordjman, E. Kisch, N. Razon, G. Ouaknine, N. Stern, Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J. Clin. Endocrinol. Metab. 80, 1577–1583 (1995)
S.M. Webb, M. Rigla, A. Wägner, B. Oliver, F. Bartumeus, Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J. Clin. Endocrinol. Metab. 84, 3696–3700 (1999)
R. Reddy, S. Cudlip, J.V. Byrne, N. Karavitaki, J.A. Wass, Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur. J. Endocrinol. 165, 739–744 (2011)
J. Honneger, U. Ernemann, T. Psaras, B. Will, Objective criteria for successful transsphenoidal removal of suprasellar nonfunctioning pituitary adenomas. A prospective study. Acta Neurochir. 149, 21–29 (2007)
M. Molitch, Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol. Clin. Metab. North Am. 37, 151–171 (2008)
N. Karavitaki, K. Collison, J. Halliday, J.V. Byrne, P. Price, S. Cudlip, J.A. Wass, What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin. Endocrinol. 67, 938–943 (2007)
J. Feldkamp, R. Santen, E. Harms, A. Aulich, U. Mödder, W.A. Scherbaum, Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas-results of a prospective study. Clin. Endocrinol. 51, 109–113 (1999)
K. Arita, A. Tominaga, K. Sugiyama, K. Eguchi, K. Iida, M. Sumida, K. Migita, K. Kurisu, Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J. Neurosurg. 104, 884–891 (2006)
O.M. Dekkers, S. Hammer, R.J.W. de Keizer, F. Roelfsema, P.J. Schutte, J.W. Smit, J.A. Romijn, A.M. Pereira, The natural course of non-functioning pituitary macroadenomas. Eur. J. Endocrinol. 156, 217–224 (2007)
Y. Greenman, G. Ouaknine, I. Veshchev, I.I. Reider-Groswasser, Y. Segev, N. Stern, Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin. Endocrinol. 58, 763–769 (2003)
E. Ferrante, M. Ferraroni, T. Castrignano, L. Menicatti, M. Anagni, G. Reimondo, P. Del Monte, D. Bernascon, P. Loli, M. Faustini-Fustini, G. Borretta, M. Terzolo, M. Losa, A. Morabito, A. Spada, P. Beck-Peccoz, A.G. Lania, Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur. J. Endocrinol. 155, 823–829 (2006)
P. Park, W. Chandler, A. Barkan, J.J. Orrego, J.A. Cowan, K.A. Griffith, C. Tsien, The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55, 100–106 (2004)
E.P. O’Sullivan, C. Woods, N. Glynn, L.A. Behan, R. Crowley, P. O’Kelly, D. Smith, C.J. Thompson, A. Agha, The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. Clin. Endocrinol. 71, 709–714 (2009)
N.J.L. Gittoes, A.S. Bates, W. Tse, B. Bullivant, M.C. Sheppard, R.N. Clayton, P.M. Stewart, Radiotherapy for non-functioning pituitary tumours. Clin. Endocrinol. 48, 331–337 (1998)
A.A. Kanner, B.W. Corn, Y. Greenman, Radiotherapy of nonfunctioning and gonadotroph adenomas. Pituitary 12, 15–22 (2009)
E.F. Chang, G. Zada, S. Kim, K.R. Lamborn, A. Quinones-Hinojosa, J.B. Tyrrell, C.B. Wilson, S. Kunwar, Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J. Neurosurg. 108, 736–745 (2008)
S. Brochier, F. Galland, M. Kujas, F. Parker, S. Gaillard, C. Raftopoulos, J. Young, O. Alexopoulou, D. Maiter, P. Chanson, Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur. J. Endocrinol. 163, 193–200 (2010)
Y. Chen, C.D. Wang, Z.P. Su, Y.X. Chen, L. Cai, Q.C. Zhuge, Z.B. Wu, Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96, 333–342 (2012)
K.J. Bradley, J.A. Wass, H.E. Turner, Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumors but do not recur more frequently. Clin. Endocrinol. 58, 59–64 (2003)
D. Erickson, B. Scheithauer, J. Atkinson, E. Horvath, K. Kovacs, R.V. Lloyd, W.F. Young Jr, Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin. Endocrinol. 71, 92–99 (2009)
G. Kontogeorgos, Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83, 179–188 (2006)
K. Thapar, K. Kovacs, B. Scheithauer, L. Stefaneanu, E. Horvath, P.J. Pernicone, D. Murray, E.R. Laws Jr, Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38, 99–107 (1996)
L. Mastronardi, A. Guiducci, C. Spera, F. Puzzilli, F. Liberati, G. Maira, Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J. Clin. Pathol. 52, 107–111 (1999)
G. Widhalm, S. Wolfsberger, M. Preusser, I. Fischer, A. Woehrer, J. Wunderer, J.A. Hainfellner, E. Knosp, Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J. Neurosurg. 111, 563–571 (2009)
C. Ramírez, S. Cheng, G. Vargas, S.L. Asa, S. Ezzat, B. González, L. Cabrera, G. Guinto, M. Mercado, Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J. Clin. Endocrinol. Metab. 97, 1745–1751 (2012)
M. Losa, A. Franzin, F. Mangili, M.R. Terreni, R. Barzaghi, F. Veglia, P. Mortini, M. Giovanelli, Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long term follow-up studies. Neurosurgery 47, 1313–1319 (2000)
S. Dubois, S. Guyetant, P. Menei, P. Rodien, F. Illouz, B. Vielle, V. Rohmer, Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur. J. Endocrinol. 157, 141–147 (2007)
J. Honegger, C. Prettin, F. Feuerhake, M. Petrick, J. Schulte-Mönting, M. Reincke, Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J. Neurosurg. 99, 674–679 (2003)
R. Gejman, B. Swearingen, E.T. Hedley-Whyte, Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum. Pathol. 38, 758–766 (2008)
K.H. Darzy, S.M. Shalet, Hypopituitarism as a consequence of brain tumours and radiotherapy. Pituitary 8, 203–211 (2005)
G. Minniti, D. Traish, S. Ashley, A. Gonsalves, M. Brada, Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenomas: update after an additional 10 years. J. Clin. Endocrinol. Metab. 90, 800–804 (2005)
E.M. Erfurth, B. Bulow, G. Svahn-Tapper, B. Norrving, K. Odh, Z. Mikoczy, J. Björk, L. Hagmar, Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J. Clin. Endocrinol. Metab. 87, 4892–4899 (2002)
J.P. Sheehan, R.M. Starke, D. Mathieu, B. Young, P.K. Sneed, V.L. Chiang, J.Y. Lee, H. Kano, K.J. Park, A. Niranjan, D. Kondziolka, G.H. Barnett, S. Rush, J.G. Golfinos, L.D. Lunsford, Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J. Neurosurg. 119, 446–456 (2013)
Y. Chen, Z.F. Li, F.X. Zhang, J.X. Li, L. Cai, Q.C. Zhuge, Z.B. Wu, Gamma knife surgery for patients with volumetric classification of nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Eur. J. Endocrinol. 169, 487–495 (2013)
D. Van Schaadenburg, F. Roefselma, A.V. Seters, G.J. Vielvoye, Bromocriptine therapy for non-functioning pituitary adenoma. Clin. Endocrinol. 30, 475–484 (1989)
A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 15, 905–915 (2008)
Z. Su, C. Wang, J. Wu, X. Jiang, Y. Chen, Y. Chen, W. Zheng, Q. Zhuge, Z. Wu, Y. Zeng, Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas. Neurol. Sci. 33, 275–279 (2012)
Y. Greenman, K. Tordjman, E. Osher, I. Veshchev, G. Shenkerman, I.I. Reider-Groswasser, Y. Segev, G. Ouaknine, N. Stern, Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin. Endocrinol. 63, 39–44 (2005)
T. Lohmann, C. Trantakis, M. Biesold, S. Prothmann, S. Guenzel, R. Schober, R. Paschke, Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 4, 173–178 (2001)
R. Pivonello, C. Matrone, M. Filippela, L.M. Cavallo, C. Di Somma, P. Cappabianca, A. Colao, L. Annunziato, G. Lombardi, Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J. Clin. Endocrinol. Metab. 89, 1674–1683 (2004)
W.W. de Herder, A.E. Reijs, R.A. Feelders, M.O. van Aken, E.P. Krenning, H.L. Tanghe, A.J. van der Lely, D.J. Kwekkeboom, Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? Eur. J. Endocrinol. 155, 717–723 (2006)
E.C. Garcia, L.A. Naves, A.O. Silva, L.F. de Castro, L.A. Casulari, M.F. Azevedo, Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 16, 189–194 (2013)
R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli, Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med. 356, 39–46 (2007)
P. Lancellotti, E. Livadariu, M. Markov, A.F. Daly, M.C. Burlacu, D. Betea, L. Pierard, A. Beckers, Cabergoline and the risk of valvular lesions in endocrine disease. Eur. J. Endocrinol. 159, 1–5 (2008)
M.C. Zatelli, D. Piccin, C. Vignalli, F. Tagliati, M.R. Ambrosio, M. Bondanelli, V. Cimino, A. Bianchi, H.A. Schmid, M. Scanarini, A. Pontecorvi, L. De Marinis, G. Maira, E.C. degli Uberti, Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 14, 91–102 (2007)
Y. Greenman, S. Melmed, Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 79, 724–729 (1994)
G. Raverot, N. Sturm, F. de Fraipont, M. Muller, S. Salenave, P. Caron, O. Chabre, P. Chanson, C. Cortet-Rudelli, R. Assaker, H. Dufour, S. Gaillard, P. François, E. Jouanneau, J.G. Passagia, M. Bernier, A. Cornélius, D. Figarella-Branger, J. Trouillas, F. Borson-Chazot, T. Brue, Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J. Clin. Endocrinol. Metab. 95, 4592–4599 (2010)
A.I. McCormack, J.A. Wass, A.B. Grossman, Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur. J. Clin. Invest. 41, 1133–1148 (2011)
G. Raverot, F. Castinetti, E. Jouanneau, I. Morange, D. Figarella-Branger, H. Dufour, J. Trouillas, T. Brue, Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin. Endocrinol. 76, 769–775 (2012)
T. Hirohata, K. Asano, Y. Ogawa, S. Takano, K. Amano, O. Isozaki, Y. Iwai, K. Sakata, N. Fukuhara, H. Nishioka, S. Yamada, S. Fujio, K. Arita, K. Takano, A. Tominaga, N. Hizuka, H. Ikeda, R.Y. Osamura, S. Tahara, Y. Ishii, T. Kawamata, A. Shimatsu, A. Teramoto, A. Matsuno, DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J. Clin. Endocrinol. Metab. 98, 1130–1136 (2013)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Greenman, Y., Stern, N. Optimal management of non-functioning pituitary adenomas. Endocrine 50, 51–55 (2015). https://doi.org/10.1007/s12020-015-0685-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-015-0685-8